Advertisement

Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma

  • Roma Patel
  • Anne Lynn S. ChangEmail author
Leading Article

Abstract

Cutaneous squamous cell carcinoma (CSCC) is one of the most common human malignancies, and the incidence is increasing with time. High mutational loads, known infiltration with lymphocytes, and programmed death (PD)-ligand 1 (PD-L1) expression suggest that immune checkpoint inhibitors, such as PD-1 inhibitors, may show utility in treating CSCC, similar to response see in other solid tumor types. Recently, the robust responsiveness of CSCCs to the PD-1 inhibitor cemiplimab was revealed in the results of a combined phase I/II clinical trial, with an overall response rate of 50% and a durable response exceeding 6 months in 57% of responders. Compared to prior systemic therapies with scant data for efficacy and safety, cemiplimab is a breakthrough therapy, the first systemic drug approved for advanced CSCCs. Other immune checkpoint inhibitors have shown promise through case reports and series, and are currently in clinical development for CSCCs.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Anne Lynn S. Chang has received research grants from Regeneron and Merck, and was an advisory board member for Regeneron and Merck. Roma Patel declares that she has no conflicts of interest that might be relevant to the contents of this article.

References

  1. 1.
    Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–66.CrossRefGoogle Scholar
  2. 2.
    Amoils M, Lee CS, Sunwoo J, Aasi SZ, Hara W, Kim J, et al. Node-positive cutaneous squamous cell carcinoma of the head and neck: survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head Neck. 2017;39(5):881–5.CrossRefGoogle Scholar
  3. 3.
    Que S, Zwald FO, Schmults C. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis and staging. J Am Acad Dermatol. 2018;78(2):237–47.CrossRefGoogle Scholar
  4. 4.
    Que S, Zwald FO, Schmults C. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249–61.CrossRefGoogle Scholar
  5. 5.
    Oldfield V, Keating GM, Perry CM. Imiquimod. Am J Clin Dermatol. 2005;6(3):195–200.CrossRefGoogle Scholar
  6. 6.
    Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–608.  https://doi.org/10.1158/1536-7163.MCT-17-0386.CrossRefGoogle Scholar
  7. 7.
    Haeffner A, Zepter K, Elmets CA, Wood GS. Analysis of tumor-infiltrating lymphocytes in cutaneous squamous cell carcinoma. JAMA Dermatol. 1997;133(5):585–90.CrossRefGoogle Scholar
  8. 8.
    Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, et al. Tumor infiltrating profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–52.CrossRefGoogle Scholar
  9. 9.
    Jarkowski A, Hare R, Loud P, Skitzki JJ, Kane JM, May KS, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and review of the literature. Am J Clin Oncol. 2016;39(6):545–8.CrossRefGoogle Scholar
  10. 10.
    Gambichler T, Gnielka M, Ruddel I, Stockfleth E, Stucker M, Schmitz L. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunol Immunother. 2017;66(9):1199–204.CrossRefGoogle Scholar
  11. 11.
    Amoils M, Kim J, Kee C, Sunwoo JB, Colevas AD, Aasi SZ, et al. PD-L1 expression and tumor-infiltrating lymphocytes in high risk and metastatic cutaneous squamous cell carcinoma. Otolaryngol Head Neck Surg.  https://doi.org/10.1177/0194599818788057.
  12. 12.
    Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.CrossRefGoogle Scholar
  13. 13.
    Chang ALS, Kim J, Luciano R, Sullivan-Chang L, Colevas AD. A case report of unresectable cutaneous squamous cell carcinoma responsive to a PD1 inhibitor. JAMA Dermatol. 2016;152(1):106–8.CrossRefGoogle Scholar
  14. 14.
    Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299–303.CrossRefGoogle Scholar
  15. 15.
    Varki V, Ioffe OB, Bentzen SM, Heath J, Cellini A, Feliciano J, et al. PD-L1, B7-H3 and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Cancer Immunol Immunother. 2018;67:805–14.CrossRefGoogle Scholar
  16. 16.
    Garcia-Pedrero J, Martinez-Camblor P, Diaz-Coto S, Munguia-Calzada P, Vallina-Alvarez A, Vazquez-Lopez F, et al. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol. 2017;77(3):527–33.CrossRefGoogle Scholar
  17. 17.
    Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016;4:70.  https://doi.org/10.1186/s40425-016-0176-3.CrossRefGoogle Scholar
  18. 18.
    Borradori L, Sutton B, Shayesteh P, Daniels G. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. Br J Dermatol. 2016;175(6):1382–6.  https://doi.org/10.1111/bjd.14642.CrossRefGoogle Scholar
  19. 19.
    Tran DC, Colevas AD, Chang ALS. Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma. JAMA Dermatol. 2016;153(1):92–4.CrossRefGoogle Scholar
  20. 20.
    Blum V, Muller B, Hofer S, Pardo E, Zeidler K, Diebold J, et al. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. Eur J Dermatol. 2018;28(1):78–91.Google Scholar
  21. 21.
    Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, Zalaudek I. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature. Eur J Cancer. 2017;83:99–102.  https://doi.org/10.1016/j.ejca.2017.06.022.CrossRefGoogle Scholar
  22. 22.
    Winkler J, Schneiderbauer R, Bender C, Sedlaczek O, Fröhling S, Penzel R, et al. Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. Br J Dermatol. 2016;176(2):498–502.  https://doi.org/10.1111/bjd.14664.CrossRefGoogle Scholar
  23. 23.
    Hauschild A, Eichstaedt J, Möbus L, Kähler K, Weichenthal M, Schwarz T, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. Eur J Cancer. 2017;77:84–7.  https://doi.org/10.1016/j.ejca.2017.02.026.CrossRefGoogle Scholar
  24. 24.
    Miller DM, Faulkner-Jones BE, Stone JR, Drews RE. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. J Am Acad Dermatol. 2017;3:412–5.Google Scholar
  25. 25.
    Migden M, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced squamous cell carcinoma. N Engl J Med. 2018;379(4):341–51.  https://doi.org/10.1056/NEJMoa1805131.CrossRefGoogle Scholar
  26. 26.
    Degache E, Crochet J, Simon N, Tardieu M, Trabelsi S, Moncourier M, et al. Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2018;32(7):e257–8.  https://doi.org/10.1111/jdv.14371.CrossRefGoogle Scholar
  27. 27.
    Merck Sharp and Dohme Corp (2018) A phase 2, open-label, single arm study to evaluate the safety and efficacy of pembrolizumab in participants with recurrent or metastatic cutaneous squamous cell carcinoma (R/M cSCC) [ClinicalTrials.gov identifier NCT03284424]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 10 Nov 2018.
  28. 28.
    Regeneron Pharmaceuticals (2018) A phase 2 study of REGN2810, a fully human monoclonal antibody to programmed death-1 (PD-1) in patients with advanced cutaneous squamous cell carcinoma [ClinicalTrials.gov identifier NCT02760498]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 10 Nov 2018.
  29. 29.
    CureVac AG (2018) Phase I study of intratumoral CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma [ClinicalTrials.gov identifier NCT02760498]. National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov. Accessed 10 Nov 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Cutaneous OncologyStanford Cancer InstituteStanfordUSA
  2. 2.Department of DermatologyStanford University School of MedicineRedwood CityUSA

Personalised recommendations